CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation

Abstract

Objective

We conducted this study to assess the role of CHA2DS2-VASc score in predicting ischemic stroke among systemic lupus erythematosus (SLE) patients without atrial fibrillation (AF).

Methods

We selected the SLE patients from the Registry of Catastrophic Illnesses Patient Database in Taiwan. We excluded the SLE patients with AF or atrial flutter. The patients were followed up until the occurrence of ischemic stroke, censored for death or withdrawal from the dataset, or the end of follow-up. Cox models were performed to obtain the hazard ratios (HRs) and the 95% confidence intervals (CIs) of ischemic stroke associated with the CHA2DS2-VASc score. A receiver operating characteristic (ROC) curve was generated to evaluate the predictive ability of CHA2DS2-VASc score for ischemic stroke in SLE patients without AF.

Results

A total of 11,962 study participants were included in this study. The incidence of ischemic stroke increased from 4.00 per 1000 person-years (PYs) for patients with a CHA2DS2-VASc score of 0 to 87.4 per 1000 PYs for those with a CHA2DS2-VASc score of ≧6. Moreover, patients with a CHA2DS2-VASc score of ≧2 were 3.98-fold (95% CI 3.15–5.04) more likely to develop ischemic stroke than those with a CHA2DS2-VASc score of <2 (14.0 vs. 2.99 per 1000 PYs). ROC curve analysis of the CHA2DS2-VASc score demonstrated a moderate discrimination power for ischemic stroke development with a c-statistic of 0.65(95% CI 0.62–0.69).

Conclusions

We found that a CHA2DS2-VASc score greater than or equal to 2 in SLE patients without AF is associated with a significantly higher rate of ischemic stroke.

Keywords

ischemic stroke systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Bartels

Buhr

Goldberg

et al.

Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014; 41: 680–687.

Ballocca

D’Ascenzo

Moretti

et al.

Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol 2015; 22: 1435–1441.

Bertoli

Vilá

Alarcón

et al.

PROFILE Study Group. Factors associated with arterial vascular events in PROFILE: a multiethnic lupus cohort. Lupus 2009; 18: 958–965.

Hak

Karlson

Feskanich

Stampfer

Costenbader

. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum 2009; 61: 1396–1402.

Mikdashi

Handwerger

Langenberg

Miller

Kittner

. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007; 38: 281–285.

Toloza

Uribe

McGwin

G Jr

et al.

LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII: baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947–3957.

Bessant

Hingorani

Patel

MacGregor

Isenberg

Rahman

. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 924–929.

Roman

Shanker

Davis

et al.

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–2406.

Asanuma

Oeser

Shintani

et al.

Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–2415.

10.

Symmons

Gabriel

. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011; 7: 399–408.

11.

Booth

Chohan

Curran

Karrison

Schmitz

Utset

. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 845–850.

12.

Tarr

Lakos

Bhattoa

Szegedi

Shoenfeld

Kiss

. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 2007; 16: 324–328.

13.

Abou-Raya

. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006; 5: 331–337.

14.

Sherer

Shoenfeld

. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99–106.

15.

Calvo-Alén

Alarcón

Tew

et al.

LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort. XXXIV: deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum 2006; 54: 1940–1945.

16.

Szalai

Alarcón

Calvo-Alén

et al.

Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005; 44: 864–868.

17.

Doria

Shoenfeld

et al.

Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071–1077.

18.

Lima

Sato

Lima

Miranda

F Jr

Hatta

. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292–297.

19.

January

Wann

Alpert

et al.

American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1–76.

20.

Ogawa

Aonuma

Tse

et al.

The APHRS’s 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013; 29: 190–200.

21.

Camm

Lip

De Caterina

et al.

ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.

22.

Lip

Nieuwlaat

Pisters

Lane

Crijns

. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.

23.

Fuster

Rydén

Cannom

et al.

2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Am Coll Cardiol 2011; 57: e101–198.

24.

Conrotto

D’Ascenzo

D’Onofrio

et al.

Predictive ability of the CHADS2 and CHA2DS2-VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. Eur J Cardiothorac Surg 2016; 50: 867–873.

25.

Hudzik

Szkodziński

Hawranek

Lekston

Poloński

Gąsior

. CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation. Acta Diabetol.. 2016;53(5):807–815.

26.

Melgaard

Gorst-Rasmussen

Lane

Rasmussen

Larsen

Lip

. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015; 314: 1030–1038.

27.

Saliba

Rennert

. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. Am J Med 2014; 127: 45–52.

28.

Mitchell

Southern

Galbraith

Ghali

Knudtson

Wilton

. APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart 2014; 100: 1524–1530.

29.

Cetin

Cakici

Zencir

et al.

Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol 2014; 113: 950–956.

30.

Paoletti Perini

Bartolini

Pieragnoli

et al.

CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace 2014; 16: 71–80.

31.

Lip

Lin

Chien

et al.

Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol 2013; 168: 414–419.

32.

Hornero

Martin

Paredes

et al.

Stroke after coronary artery bypass grafting: preoperative predictive accuracies of CHADS2 and CHA2DS2VASc stroke risk stratification schemes. J Thorac Cardiovasc Surg 2012; 144: 1428–1435.

33.

Podolecki

Lenarczyk

Kowalczyk

et al.

Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation. J Cardiovasc Med (Hagerstown) 2015; 16: 497–502.

34.

Ntaios

Lip

Makaritsis

et al.

CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013; 80: 1009–1017.

35.

National Health Research Institutes. National Health Insurance Research Database. http://nhird.nhri.org.tw/en/index.html. (accessed 14 April 2015).

36.

Huang

Kuan

Luo

Lin

Liang

Kao

. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med 2016; 32: 91–95.

37.

Shen

Lin

Chen

et al.

Increased risk of chronic obstructive pulmonary disease in patients with systemic lupus erythematosus: a population-based cohort study. PLoS One 2014; 9: e91821–e91821.

38.

Lin

. Comparison of CHA2DS2-VASc, CHADS2 and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients: a nationwide cohort study of 760,339 study participants with competing risk analysis. Atherosclerosis 2017; 266: 205–211.

39.

Lin

. CHA2DS2-VASc score in the prediction of ischemic bowel disease among patients with atrial fibrillation: insights from a nationwide cohort. Int J Cardiol 2017; 235: 56–60.

40.

Lin

. Postoperative ischemic stroke and death prediction with CHA2DS2-VASc score in patients having coronary artery bypass grafting surgery: a nationwide cohort study. Int J Cardiol 2017; 241: 120–123.